RLMD News and Press, Relmada Therapeutics Inc. From 06/25/20

The following slide deck was published by Relmada Therapeutics, Inc. in conjunction with this Read more ...

Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms Canada NewsWire NEW YORK, June 23, 2020 Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antag...

NEW YORK , June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will participate i...

NEW YORK , May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will present ...

NEW YORK , May 27, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the completion of its End-of-Phase 2 meeting with the U.S. Food and ...

NEW YORK , May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Molly Harper as Executive Vice President of Operatio...

Every year, about 17.3 million adults in the U.S. will experience at least one major depressive episode. Approximately 1 in 3 will fail to see improvement in their symptoms after treatment involving at least two different types of medications, and will be diagnosed with a condition called treatm...

How I started 2020 with a smile and cash reserves In the beginning of January, I was full of enthusiasm for the stock market, not only in the U.S. but also in Europe, specifically for the Eurozone and in Poland. Not so much because of the climbing S&P 500 levels, as for my eagerness to p...

Aeglea BioTherapeutics (NASDAQ: AGLE ) initiated with Overweight rating and $12 (60% upside) price target at Piper Sandler. More news on: Aeglea BioTherapeutics, Inc., Keros Therapeutics, Inc., Novo Nordisk A/S, Healthcare stocks news, Stocks on the move, , Read more ...

NEW YORK , April 28, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter , Ph.D., as Vice President of Regul...